2023
DOI: 10.1016/j.diagmicrobio.2022.115854
|View full text |Cite
|
Sign up to set email alerts
|

Emerging multidrug resistance contributes to treatment failure in Mycoplasma genitalium infected patients in China

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

1
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 29 publications
1
1
0
Order By: Relevance
“…While fluoroquinolone resistance may not always lead to treatment failure, certain patients may still respond favourably to moxifloxacin treatment. Nevertheless, instances of clinical multidrug-resistant M. genitalium infections are increasingly being documented in many countries [22,23], and here, we observed that this is the emerging problem in Croatia as well. Alternative therapies such as minocycline, pristinamycin and chloramphenicol are considered third-line options [24]; however, accessing these drugs is challenging in Croatia and other European countries.…”
Section: Discussionsupporting
confidence: 56%
“…While fluoroquinolone resistance may not always lead to treatment failure, certain patients may still respond favourably to moxifloxacin treatment. Nevertheless, instances of clinical multidrug-resistant M. genitalium infections are increasingly being documented in many countries [22,23], and here, we observed that this is the emerging problem in Croatia as well. Alternative therapies such as minocycline, pristinamycin and chloramphenicol are considered third-line options [24]; however, accessing these drugs is challenging in Croatia and other European countries.…”
Section: Discussionsupporting
confidence: 56%
“…30 The latest data from the same region show that the rRNA gene had a mutation rate of 64% in 23S, and that of the parC gene was 67.5%. 31 The above data show no significant change in the mutation rate. A survey of male patients with STIs in Hong Kong, China, showed that the mutation rate of 23S rRNA was 47% and that of parC was 53%.…”
Section: Discussionmentioning
confidence: 70%
“…However, there is still debate on how to predict the therapeutic response to fluoroquinolones by MG genotypes, as studies have not found a strong concordance between them (Manhart and Jensen, 2020;Sweeney et al, 2022). In China, our previous study showed that the prevalence rate of 23S rRNA mutations at A2058 and A2059 positions in MG samples was 64%, and the amino acid substitution rate of parC S83 and D87 was 67.5% (Li et al, 2023). In such areas with high mutation rates, it is particularly important to try to estimate both macrolide and fluoroquinolone resistance.…”
Section: Discussionmentioning
confidence: 99%